- Home
- IFRX vs IKT Comparison
IFRX vs IKT Comparison
Compare IFRX & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- IKT
- Stock Information
- Founded
- IFRX 2007
- IKT 2008
- Country
- IFRX Germany
- IKT United States
- Employees
- IFRX N/A
- IKT N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- IKT Health Care
- Exchange
- IFRX Nasdaq
- IKT Nasdaq
- Market Cap
- IFRX 117.8M
- IKT 167.2M
- IPO Year
- IFRX 2017
- IKT 2020
- Fundamental
- Price
- IFRX $1.15
- IKT $2.20
- Analyst Decision
- IFRX Strong Buy
- IKT Buy
- Analyst Count
- IFRX 1
- IKT 2
- Target Price
- IFRX $8.00
- IKT $8.00
- AVG Volume (30 Days)
- IFRX 623.9K
- IKT 167.2K
- Earning Date
- IFRX 05-07-2025
- IKT 03-26-2025
- Dividend Yield
- IFRX N/A
- IKT N/A
- EPS Growth
- IFRX N/A
- IKT N/A
- EPS
- IFRX N/A
- IKT N/A
- Revenue
- IFRX $187,930.00
- IKT $1.00
- Revenue This Year
- IFRX $396.02
- IKT N/A
- Revenue Next Year
- IFRX $155.22
- IKT N/A
- P/E Ratio
- IFRX N/A
- IKT N/A
- Revenue Growth
- IFRX 177.12
- IKT N/A
- 52 Week Low
- IFRX $1.14
- IKT $1.12
- 52 Week High
- IFRX $2.82
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- IFRX 24.46
- IKT 45.02
- Support Level
- IFRX $1.76
- IKT $1.91
- Resistance Level
- IFRX $1.34
- IKT $2.22
- Average True Range (ATR)
- IFRX 0.14
- IKT 0.25
- MACD
- IFRX -0.01
- IKT -0.01
- Stochastic Oscillator
- IFRX 1.39
- IKT 29.59
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.